Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE  
110.93
+4.22 (+3.96%)
Other Pre-Announcement

Ultragenyx Reports Q1 2021 Financial Results And Corporate Update

Published: 05/04/2021 20:35 GMT
Ultragenyx Pharmaceutical Inc. (RARE) - Ultragenyx Reports First Quarter 2021 Financial Results and Corporate Update.
Q1 Revenue $99.4 Million.
Reaffirms 2021 Guidance Range for Crysvita That Was Provided at Beginning of Year.
Reaffirms 2021 Guidance Range for Crysvita That Was Provided at Beginning of Year.
Cash, Cash Equivalents, and Marketable Debt Securities Were $1.0 Billion As of March 31, 2021.